OPEN Foundation

Survey: New Drugs for Mental Health

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

After the recent published study on psychedelic substances and mental health, researchers are looking to explore this relation more deeply. The main aim of the survey is to gain novel insight towards un-noted benefits (and harms) of recreationally used drugs on mental health.

This survey was created by Imperial college, Prof D. Nutt, Dr R. Carhart-Harris and their team. According to the researchers, little is yet known about the effects on mental health of people who experiment with psychedelic substances. They are asking questions to gather information about potential usefulness for mental health of these new drugs and also to discover whether they have any unrecognised negative effects. Please click this link to participate in this recently launched online survey regarding psychoactive drugs and mental health.

Participants can fill in a different survey for each drug they want to say something about. Please only complete a survey if you have personal experience with a particular drug.

Responses will be treated as clinical information and are protected by medical confidentiality law. Your personal details will not be requested or stored.

OPEN Foundation

Join ICPR 2022 Online!

ICPR features world-leading experts from many academic disciplines, including psychiatry, psychology, neuroscience, anthropology, ethnobotany, and philosophy who come together to give a scientific conference for academics, therapists, researchers, clinicians, policymakers, and members of the public. Get your ICPR 2022 livestream ticket today and use the code OPENLIVE30 at checkout for a €30 discount.

Learn More

INTERESTED IN PSYCHEDELIC RESEARCH AND THERAPIES?

Subscribe to our new OPEN-Minded newsletter to stay in the loop, hear about our events, and become a part of a community dedicated to advancing psychedelics.

By clicking subscribe, I confirm to receive emails from the OPEN Foundation and agree with its privacy policy.

30 April - Q&A with Rick Strassman

X